A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

NCT01958671 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

461

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Ertugliflozin 5 mg
DRUG: Ertugliflozin 10 mg
DRUG: Placebo to Ertugliflozin
DRUG: Metformin
DRUG: Placebo to Metformin
DRUG: Glimepiride

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]